Phase IIa success for EnteroBiotix microbiome product

18 March 2025

Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C).

The multicenter, randomized, double-blind, placebo-controlled TrIuMPH study assessed the safety, tolerability, and preliminary efficacy of EBX-102-02 in 122 patients with moderate to severe IBS-C and IBS with diarrhoea (IBS-D). 

Patients were randomized two-to-one to receive either eight capsules of EBX-102-02 on each of day one and day seven, or a matched placebo, and were followed up for six weeks after the first dose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical